Akari Therapeutics Plc
AKTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AKTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AKTX
Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel payload biology, with no approved products or revenue to date [sec_mda · as of 2026-03-30].
Key risk: No clinical-stage pipeline
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 clinical trial for Akari Therapeutics Plc.
Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel payload biology, with no approved products or revenue to date [sec_mda · as of 2026-03-30].
- Akari is an oncology company focused on next-generation ADCs with novel payload biology [sec_mda · as of 2026-03-30].
- As of 2026-06-30, the company reported cash & equivalents of $7.8M, shareholders' equity of $28.3M, and total debt of $0.7M [sec].
- The company has not initiated clinical studies for any programs in its active pipeline and has not entered into strategic partnerships for legacy pipeline assets [sec · filed 2026-07-02].
- Akari has incurred substantial losses since inception, with an accumulated deficit of $264.5M as of December 31, 2025, and has not generated any revenue [sec_mda · as of 2026-03-30].
- The company has identified material weaknesses in its internal control over financial reporting [sec · filed 2026-07-02].
What works
- The company is developing next-generation ADCs with novel payload biology, which may represent a differentiated approach in oncology [sec_mda · as of 2026-03-30].
- As of 2026-06-30, the company had $7.8M in cash and equivalents, providing some near-term liquidity [sec].
- Total debt is low at $0.7M as of 2026-06-30, indicating limited leverage [sec].
What to weigh
- The company has not initiated clinical studies for any programs in its active pipeline, suggesting early-stage development [sec · filed 2026-07-02].
- Akari has an accumulated deficit of $264.5M as of December 31, 2025, with no revenue generated to date [sec_mda · as of 2026-03-30].
- The company has identified material weaknesses in internal control over financial reporting [sec · filed 2026-07-02].
- It may be years before the company commercializes a product candidate, if ever [sec · filed 2026-07-02].
From the filings
Quoted directly from source documents.
The company is an oncology company developing next-generation ADCs.
“We are an oncology company developing next generation ADCs designed around novel payload biology.”
SEC MD&A · March 30, 2026
The company has not initiated clinical studies for any programs in its active pipeline.
“We have not initiated clinical studies for any of the programs in our active pipeline or entered into any strategic partnerships regarding the continued development of our legacy pipeline assets.”
SEC filings · July 2, 2026
The company has incurred substantial losses and has an accumulated deficit.
“At December 31, 2025, we had $5.2 million in cash and an accumulated deficit of $264.5 million. To date, we have not generated any revenue.”
SEC MD&A · March 30, 2026
The company has material weaknesses in internal control over financial reporting.
“weaknesses in our internal control over financial reporting;”
SEC filings · July 2, 2026
Risks & what to watch (4)›
Key risks
- No clinical-stage pipeline — The company has not initiated clinical studies for any active pipeline programs, indicating very early-stage development [sec · filed 2026-07-02].
- Substantial accumulated losses — Accumulated deficit of $264.5M as of December 31, 2025, with no revenue generated, raising going-concern risk [sec_mda · as of 2026-03-30].
- Internal control weaknesses — Material weaknesses in internal control over financial reporting have been identified [sec · filed 2026-07-02].
- Uncertain commercialization timeline — It may be years before a product candidate is commercialized, if ever [sec · filed 2026-07-02].
What to watch
- Initiation of any clinical trials for pipeline programs [sec · filed 2026-07-02].
- Progress in resolving material weaknesses in internal controls [sec · filed 2026-07-02].
- Cash runway and potential need for additional financing given $7.8M cash as of 2026-06-30 [sec].
- Any strategic partnerships or licensing deals for legacy or current pipeline assets [sec · filed 2026-07-02].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Akari Therapeutics Plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Akari Therapeutics Plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
7.6 months
D/E 1.08 · 0% dilution
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$200K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 38,922 | $200K |
| morgan stanley | 1 | $5 |
| truvestments capital llc | 1 | $5 |
Short Interest
as of Apr 21, 2026- % of float
- 1.8%
- Days to cover
- 0.5
- Shares short
- 5,810
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AKTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Akari Therapeutics Plc?
Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel payload biology, with no approved products or revenue to date [sec_mda · as of 2026-03-30].
What is Akari Therapeutics Plc's lead drug candidate?
Akari Therapeutics Plc's most advanced tracked candidate is aktx-101 (Preclinical) for Solid tumors (including lung, breast, urothelial, gastric, pancreatic, and others).
Who is the CEO of Akari Therapeutics Plc?
Mr. Abizer Gaslightwala is the chief executive officer of Akari Therapeutics Plc (AKTX).
Where is Akari Therapeutics Plc headquartered?
Akari Therapeutics Plc (AKTX) is headquartered in Tampa, FL, United States.
What therapeutic areas does Akari Therapeutics Plc focus on?
Akari Therapeutics Plc develops therapies across Oncology, Neurology, Hematology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.